Table 3. Summary of clinical performance of methylation biomarker, HPV and CA-IX.
| Testing | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| SOX1 | 100 | 67 | 30 | 100 |
| POU4F3 | 100 | 52 | 24 | 100 |
| HPV(HC2) | 57 | 75 | 25 | 92 |
| CA-IX* , a | 75 | 88 | 70 | 90 |
| CA-IX** , a | 89 | 47 | 55 | 86 |
| HPV(HC2)* , a | 97 | 87 | 77 | 99 |
| HPV(PCR)** , a | 65 | 86 | 76 | 78 |
| HPV+CA-IX* , a | 97 | 80 | 69 | 99 |
| HPV+CA-IX** , a | 97 | 42 | 53 | 95 |
Abbreviations: HPV, human papilloma virus; CA-IX, carbonic anhydrase-IX.
aThe studies is only using significant cervical lesion, reflects the presence of CIN2, CIN3, AIS or invasive carcinoma.
*Int. J. Cancer: 125, 2434–2440 (2009)
**British Journal of Cancer 104, 353–360 (2011)